Pfizer Prepares For Year-End US Bevacizumab Launch
Executive Summary
Pfizer has cleared the way to launching its Zirabev bevacizumab biosimilar in the US on 31 December this year following a patent-litigation settlement with Roche.
Topics
- Subjects
- Biosimilars
- Launches
- Intellectual Property
- Biologics
- Commercial
- Companies
- Legal Issues
- Regions
- North America
- Therapy Areas
- Cancer
- Industries
- BioPharmaceutical
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GB149205
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.
All fields are required.
GB149205
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.